Free Trial
→ Trump goes 'all-in' on Grand Canyon energy breakthrough (From Behind the Markets) (Ad)tc pixel Free KROS Stock Alerts

Keros Therapeutics (KROS) Financials

Keros Therapeutics logo
$11.95 +0.31 (+2.66%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$11.98 +0.03 (+0.21%)
As of 10/9/2026 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Keros Therapeutics

Annual Income Statements for Keros Therapeutics

This table shows Keros Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -12 -45 -59 -105 -153 -187 87
Consolidated Net Income / (Loss)		 -12 -45 -59 -105 -153 -187 87
Net Income / (Loss) Continuing Operations		 -12 -45 -59 -105 -153 -187 87
Total Pre-Tax Income 		-12 -46 -57 -105 -153 -187 92
Total Operating Income		 -11 -47 -56 -115 -170 -211 68
Total Gross Profit		 10 0.00 20 0.00 0.15 3.55 244
Total Revenue		 10 0.00 20 0.00 0.15 3.55 244
Operating Revenue		 10 0.00 20 0.00 0.15 3.55 244
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 21 47 76 115 170 214 176
Selling, General & Admin Expense		 3.18 13 21 28 35 41 47
Research & Development Expense		 17 34 55 87 135 174 130
Total Other Income / (Expense), net		 -1.77 1.12 -0.36 10 17 24 24
Interest & Investment Income		 -0.01 2.46 0.03 11 15 23 25
Other Income / (Expense), net		 -1.77 -1.33 -0.38 -0.61 2.19 0.28 -0.54
Income Tax Expense		 0.00 -0.17 2.01 0.00 0.00 0.30 4.88
Basic Earnings per Share		 ($6.08) ($2.93) ($2.52) ($4.15) ($5.20) ($5.00) $2.34
Weighted Average Basic Shares Outstanding		 2.33M 15.51M 23.33M 25.24M 29.45M 37.44M 37.22M
Diluted Earnings per Share		 ($6.08) ($2.93) ($2.52) ($4.15) ($5.20) ($5.00) $2.30
Weighted Average Diluted Shares Outstanding		 2.33M 15.51M 23.33M 25.24M 29.45M 37.44M 37.86M
Weighted Average Basic & Diluted Shares Outstanding		 2.33M 15.51M 24.00M 28.54M 35.98M 40.56M 19.72M

Quarterly Income Statements for Keros Therapeutics

This table shows Keros Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -40 -43 -45 -53 -46 148 -31 -7.28 -23 -24 -29
Consolidated Net Income / (Loss)		 -40 -43 -45 -53 -46 148 -31 -7.28 -23 -24 -29
Net Income / (Loss) Continuing Operations		 -40 -43 -45 -53 -46 148 -31 -7.28 -23 -24 -29
Total Pre-Tax Income 		-40 -43 -45 -53 -46 158 -33 -8.70 -25 -24 -29
Total Operating Income		 -46 -48 -50 -59 -53 152 -40 -15 -29 -26 -31
Total Gross Profit		 0.14 0.08 0.04 0.39 3.04 211 18 14 0.39 0.37 0.00
Total Revenue		 0.14 0.08 0.04 0.39 3.04 211 18 14 0.39 0.37 0.00
Operating Revenue		 0.14 0.08 0.04 0.39 3.04 211 18 14 0.39 0.37 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 47 49 50 59 56 59 58 30 30 26 31
Selling, General & Admin Expense		 9.11 10 9.96 9.82 11 10 14 10 12 10 8.61
Research & Development Expense		 37 38 41 49 46 49 44 20 18 16 22
Total Other Income / (Expense), net		 6.21 5.37 5.18 5.70 7.53 6.45 6.90 6.68 4.30 2.17 2.23
Interest & Investment Income		 3.76 5.81 5.38 5.79 7.76 6.79 7.12 6.93 4.02 2.34 2.29
Other Income / (Expense), net		 2.46 -0.44 -0.20 -0.09 -0.23 -0.34 -0.22 -0.25 0.27 -0.17 -0.06
Income Tax Expense		 - 0.00 0.00 0.00 - 10 -2.22 -1.42 -1.51 0.00 0.00
Basic Earnings per Share		 ($1.34) ($1.21) ($1.25) ($1.41) ($1.13) $3.66 ($0.76) ($0.18) ($0.38) ($1.21) ($1.45)
Weighted Average Basic Shares Outstanding		 29.45M 35.69M 36.10M 37.59M 37.44M 40.56M 40.61M 40.62M 37.22M 19.63M 19.80M
Diluted Earnings per Share		 ($1.34) ($1.21) ($1.25) ($1.41) ($1.13) $3.62 ($0.76) ($0.18) ($0.38) ($1.21) ($1.45)
Weighted Average Diluted Shares Outstanding		 29.45M 35.69M 36.10M 37.59M 37.44M 41.02M 40.61M 40.62M 37.86M 19.63M 19.80M
Weighted Average Basic & Diluted Shares Outstanding		 35.98M 36.08M 37.52M 40.51M 40.56M 40.62M 40.62M 30.47M 19.72M 19.79M 19.83M

Annual Cash Flow Statements for Keros Therapeutics

This table details how cash moves in and out of Keros Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -16 259 -35 49 52 229 -273
Net Cash From Operating Activities		 -16 -37 -62 -70 -125 -161 108
Net Cash From Continuing Operating Activities		 -16 -37 -62 -70 -125 -160 107
Net Income / (Loss) Continuing Operations		 -12 -45 -59 -105 -153 -187 87
Consolidated Net Income / (Loss)		 -12 -45 -59 -105 -153 -187 87
Depreciation Expense		 0.21 0.28 0.38 0.67 0.82 1.23 1.51
Non-Cash Adjustments To Reconcile Net Income		 2.09 6.84 12 16 29 35 29
Changes in Operating Assets and Liabilities, net		 -5.96 1.35 -15 18 -3.03 -10 -10
Net Cash From Investing Activities		 -0.27 -0.29 -1.02 -1.24 -2.46 -1.93 -1.55
Net Cash From Continuing Investing Activities		 -0.27 -0.29 -1.02 -1.24 -2.46 -1.93 -1.56
Purchase of Property, Plant & Equipment		 -0.27 -0.29 -1.02 -1.24 -2.46 -1.93 -1.56
Net Cash From Financing Activities		 0.01 296 29 120 179 392 -378
Net Cash From Continuing Financing Activities		 0.01 296 29 120 179 392 -375
Repurchase of Common Equity		 0.00 -0.23 - -0.09 -0.09 -0.17 -375
Issuance of Common Equity		 0.00 243 28 120 176 380 0.14
Other Financing Activities, net		 0.01 -2.51 0.38 0.82 3.23 12 0.15
Cash Income Taxes Paid		 0.26 - - - - 0.00 7.15

Quarterly Cash Flow Statements for Keros Therapeutics

This table details how cash moves in and out of Keros Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 43 111 -37 125 29 161 -30 3.26 -406 -5.92 -24
Net Cash From Operating Activities		 -25 -45 -40 -31 -46 161 -30 3.25 -27 -3.53 -20
Net Cash From Continuing Operating Activities		 -26 -44 -39 -30 -46 161 -29 1.99 -27 -3.53 -20
Net Income / (Loss) Continuing Operations		 -40 -43 -45 -53 -46 148 -31 -7.28 -23 -24 -29
Consolidated Net Income / (Loss)		 -40 -43 -45 -53 -46 148 -31 -7.28 -23 -24 -29
Depreciation Expense		 0.25 0.28 0.31 0.31 0.33 0.34 0.37 0.40 0.40 0.40 0.40
Non-Cash Adjustments To Reconcile Net Income		 7.32 8.07 8.79 8.82 9.20 9.45 8.53 3.99 7.31 6.84 6.03
Changes in Operating Assets and Liabilities, net		 6.75 -9.89 -3.66 13 -9.66 2.93 -7.96 6.06 -12 13 1.86
Net Cash From Investing Activities		 -0.54 -0.95 -0.31 -0.39 -0.29 -0.57 -0.72 -0.13 -0.13 -0.07 -0.16
Net Cash From Continuing Investing Activities		 -0.54 -0.95 -0.31 -0.39 -0.29 -0.57 -0.72 -0.14 -0.13 -0.07 -0.16
Purchase of Property, Plant & Equipment		 -0.54 -0.95 -0.31 -0.39 -0.29 -0.57 -0.72 -0.14 -0.13 -0.07 -0.16
Net Cash From Financing Activities		 69 157 3.53 156 76 0.00 0.02 0.14 -379 -2.32 -3.32
Net Cash From Continuing Financing Activities		 69 157 3.56 156 76 0.00 0.02 0.14 -375 -2.32 -3.32
Repurchase of Common Equity		 -0.07 - - -0.13 - 0.00 - - -375 -2.32 -3.34
Other Financing Activities, net		 0.80 5.72 2.97 1.01 2.45 0.00 0.02 0.00 0.13 0.01 0.02

Annual Balance Sheets for Keros Therapeutics

This table presents Keros Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 11 269 255 307 370 616 338
Total Current Assets		 8.93 268 251 286 347 589 315
Cash & Equivalents		 7.02 266 230 279 331 560 287
Accounts Receivable		 - - 18 0.00 0.14 2.74 3.57
Prepaid Expenses		 0.38 1.85 3.40 6.72 16 26 22
Current Deferred & Refundable Income Taxes		 - - - - - 0.00 2.25
Plant, Property, & Equipment, net		 0.71 0.72 1.34 2.02 4.13 4.24 4.30
Total Noncurrent Assets		 1.32 0.99 2.48 19 19 23 18
Other Noncurrent Operating Assets		 1.32 0.99 2.48 19 19 23 18
Total Liabilities & Shareholders' Equity		 11 269 255 307 370 616 338
Total Liabilities		 10 7.72 12 29 38 44 35
Total Current Liabilities		 4.49 7.18 12 17 24 27 20
Accounts Payable		 2.09 2.15 3.65 3.34 5.45 4.60 1.97
Accrued Expenses		 2.02 4.61 7.34 13 18 21 16
Other Current Liabilities		 0.38 0.42 0.86 0.46 1.01 1.98 2.41
Total Noncurrent Liabilities		 5.97 0.54 0.23 13 13 17 14
Other Noncurrent Operating Liabilities		 5.97 0.54 0.23 13 13 17 14
Total Equity & Noncontrolling Interests		 -19 262 243 277 332 572 303
Total Preferred & Common Equity		 -19 262 243 277 332 572 303
Preferred Stock		 - - - 0.00 0.00 0.00 0.00
Total Common Equity		 -19 262 243 277 332 572 303
Common Stock		 0.20 327 367 506 714 1,140 1,169
Retained Earnings		 -20 -65 -124 -228 -381 -569 -482
Treasury Stock		 - - - - - - -385

Quarterly Balance Sheets for Keros Therapeutics

This table presents Keros Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 384 356 326 486 455 579 785 757 743 312 288
Total Current Assets		 362 334 304 463 433 552 760 733 719 291 267
Cash & Equivalents		 351 322 288 442 406 531 721 690 693 281 258
Accounts Receivable		 - - - 0.23 0.00 0.39 17 16 3.49 0.40 0.00
Prepaid Expenses		 11 12 17 20 27 21 22 27 22 6.53 7.03
Current Deferred & Refundable Income Taxes		 - - - - - - - - - 2.25 2.25
Plant, Property, & Equipment, net		 2.93 3.09 3.36 4.43 4.29 4.37 4.47 4.84 4.56 3.96 3.72
Total Noncurrent Assets		 19 19 18 18 18 23 21 20 19 18 17
Other Noncurrent Operating Assets		 19 19 18 18 18 23 21 20 19 18 17
Total Liabilities & Shareholders' Equity		 384 356 326 486 455 579 785 757 743 312 288
Total Liabilities		 29 30 30 32 34 46 56 50 39 27 25
Total Current Liabilities		 15 16 17 19 21 29 39 35 24 13 12
Accounts Payable		 4.68 4.15 3.87 4.99 6.54 4.98 6.64 5.27 2.30 1.49 1.82
Accrued Expenses		 11 12 12 13 14 22 17 20 15 8.86 7.74
Other Current Liabilities		 0.00 0.00 0.61 1.05 1.10 1.86 2.10 2.23 2.32 2.50 2.60
Total Noncurrent Liabilities		 14 14 14 13 13 17 16 16 15 14 13
Other Noncurrent Operating Liabilities		 14 14 14 13 13 17 16 16 15 14 13
Total Equity & Noncontrolling Interests		 355 326 296 454 421 533 729 707 704 286 262
Total Preferred & Common Equity		 355 326 296 454 421 533 729 707 704 286 262
Preferred Stock		 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 355 326 296 454 421 533 729 707 704 286 262
Common Stock		 619 628 637 878 891 1,056 1,149 1,158 1,162 1,176 1,181
Retained Earnings		 -264 -302 -341 -425 -470 -523 -420 -451 -458 -505 -534
Treasury Stock		 - - - - - - - - - -385 -385

Annual Metrics And Ratios for Keros Therapeutics

This table displays calculated financial ratios and metrics derived from Keros Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 20,188,351.00 23,398,657.00 - - - 30,466,069.00
DEI Adjusted Shares Outstanding		 0.00 20,188,351.00 23,398,657.00 - - - 30,466,069.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -2.25 -2.51 - - - 2.86
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% -100.00% 0.00% 2,250.99% 6,774.96%
EBITDA Growth		 0.00% -293.64% -17.08% -105.39% -44.15% -26.22% 133.03%
EBIT Growth		 0.00% -289.25% -18.27% -103.33% -45.36% -26.25% 131.84%
NOPAT Growth		 0.00% -341.70% -20.82% -103.63% -48.05% -24.06% 143.35%
Net Income Growth		 0.00% -267.71% -29.50% -78.20% -46.15% -22.46% 146.44%
EPS Growth		 0.00% 51.81% 13.99% -64.68% -25.30% 3.85% 146.00%
Operating Cash Flow Growth		 0.00% -130.62% -68.45% -12.73% -77.71% -29.20% 166.83%
Free Cash Flow Firm Growth		 0.00% 0.00% -62.00% -15.59% -85.45% -30.00% 137.87%
Invested Capital Growth		 0.00% 36.32% 416.05% -112.37% 165.60% 990.24% 35.23%
Revenue Q/Q Growth		 0.00% 0.00% 20,000.00% 0.00% 1,787.50% 445.31% -1.08%
EBITDA Q/Q Growth		 0.00% 0.00% 23.40% 0.00% -6.87% -4.59% 55.82%
EBIT Q/Q Growth		 0.00% 0.00% 22.54% 0.00% -7.91% -4.69% 57.55%
NOPAT Q/Q Growth		 0.00% 0.00% 22.94% 0.00% -9.32% -3.33% 62.04%
Net Income Q/Q Growth		 0.00% 0.00% 17.01% 0.00% -7.39% -3.19% 35.01%
EPS Q/Q Growth		 0.00% 0.00% -396.47% 0.00% -5.05% 4.03% 48.39%
Operating Cash Flow Q/Q Growth		 0.00% -7.25% -22.89% 0.00% -3.33% -14.64% 21.08%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -2,184.78% -4.19% -15.41% 89.95%
Invested Capital Q/Q Growth		 0.00% 0.00% 557.40% 0.00% -86.59% 440.31% 55.49%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 0.00% 100.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -121.20% 0.00% -277.90% 0.00% -109,523.18% -5,879.94% 28.08%
Operating Margin		 -105.63% 0.00% -280.46% 0.00% -112,543.71% -5,938.96% 27.69%
EBIT Margin		 -123.28% 0.00% -282.37% 0.00% -111,090.73% -5,965.83% 27.46%
Profit (Net Income) Margin		 -123.36% 0.00% -292.26% 0.00% -101,319.21% -5,277.55% 35.65%
Tax Burden Percent		 100.00% 99.62% 103.54% 100.00% 100.00% 100.16% 94.69%
Interest Burden Percent		 100.06% 94.89% 99.96% 90.71% 91.20% 88.32% 137.10%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.31%
Return on Invested Capital (ROIC)		 0.00% 0.00% -879.16% 0.00% 0.00% -2,326.34% 468.04%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -871.38% 0.00% 0.00% -2,317.42% 462.60%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 855.89% 0.00% 0.00% 2,284.88% -448.14%
Return on Equity (ROE)		 -2,492.12% -34.60% -23.27% -40.22% -50.19% -41.46% 19.90%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -432.14% 0.00% -11,411.79% -2,492.73% 438.08%
Operating Return on Assets (OROA)		 -112.53% 0.00% -21.63% 0.00% -49.57% -42.96% 14.05%
Return on Assets (ROA)		 -112.61% 0.00% -22.39% 0.00% -45.21% -38.01% 18.24%
Return on Common Equity (ROCE)		 97,902.60% -31.97% -23.27% -40.22% -50.19% -41.46% 19.90%
Return on Equity Simple (ROE_SIMPLE)		 63.44% -17.33% -24.16% -37.73% -46.05% -32.78% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.39 -33 -39 -80 -119 -148 64
NOPAT Margin		 -73.94% 0.00% -196.32% 0.00% -78,780.60% -4,157.27% 26.21%
Net Nonoperating Expense Percent (NNEP)		 -70.40% -9.31% -7.78% -9.56% -11.15% -8.93% 5.44%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -28.96% -35.81% -25.82% 21.11%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 31.84% 0.00% 106.12% 0.00% 23,068.87% 1,148.00% 19.20%
R&D to Revenue		 173.79% 0.00% 274.34% 0.00% 89,574.83% 4,890.96% 53.12%
Operating Expenses to Revenue		 205.63% 0.00% 380.46% 0.00% 112,643.71% 6,038.96% 72.31%
Earnings before Interest and Taxes (EBIT)		 -12 -48 -57 -115 -168 -212 67
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 -48 -56 -115 -165 -209 69
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 5.44 5.63 4.46 3.59 1.12 2.05
Price to Tangible Book Value (P/TBV)		 0.00 5.44 5.63 4.46 3.59 1.12 2.05
Price to Revenue (P/Rev)		 9.60 0.00 68.11 0.00 7,888.64 180.63 2.54
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 7.13
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 14.03%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 86.74 0.00 806.79 7.00 21.18
Enterprise Value to Revenue (EV/Rev)		 10.89 0.00 56.67 0.00 5,695.62 22.90 1.36
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 4.86
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 4.97
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 5.20
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 3.10
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 5.56
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -14.18 -1.04 -0.98 -0.98 -1.00 -0.99 -0.97
Leverage Ratio		 22.13 1.07 1.04 1.08 1.11 1.09 1.09
Compound Leverage Factor		 22.15 1.01 1.04 0.98 1.01 0.96 1.50
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 4,028.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -3,928.48% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.68 110.89 67.81 24.05 17.01 7.35 11.10
Noncontrolling Interest Sharing Ratio		 4,028.48% 7.60% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 1.99 37.27 21.23 17.27 14.25 21.45 15.45
Quick Ratio		 1.56 37.01 20.94 16.86 13.59 20.50 14.25
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -35 -57 -66 -122 -158 60
Operating Cash Flow to CapEx		 -5,903.32% -12,548.98% -6,069.14% -5,645.61% -5,053.08% -8,330.86% 6,909.06%
Free Cash Flow to Firm to Interest Expense		 0.00 -5,838.32 -14,187.03 -65,596.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -6,149.00 -15,537.00 -70,062.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -6,198.00 -15,793.00 -71,303.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.91 0.00 0.08 0.00 0.00 0.01 0.51
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 2.46 77.37
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 14.12 0.00 19.52 0.00 0.05 0.85 57.20
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 148.31 4.72
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 148.31 4.72
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -6.53 -4.16 13 -1.63 1.07 12 16
Invested Capital Turnover		 -1.53 0.00 4.48 0.00 -0.54 0.56 17.85
Increase / (Decrease) in Invested Capital		 0.00 2.37 17 -15 2.69 11 4.10
Enterprise Value (EV)		 109 1,158 1,139 958 860 81 333
Market Capitalization		 96 1,424 1,369 1,237 1,191 641 620
Book Value per Share		 ($8.36) $12.96 $10.39 $10.99 $11.09 $14.11 $9.95
Tangible Book Value per Share		 ($8.36) $12.96 $10.39 $10.99 $11.09 $14.11 $9.95
Total Capital		 0.50 262 243 277 332 572 303
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -7.02 -266 -230 -279 -331 -560 -287
Capital Expenditures (CapEx)		 0.27 0.29 1.02 1.24 2.46 1.93 1.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.58 -5.33 9.55 -9.83 -8.23 1.51 7.61
Debt-free Net Working Capital (DFNWC)		 4.44 261 240 269 323 561 295
Net Working Capital (NWC)		 4.44 261 240 269 323 561 295
Net Nonoperating Expense (NNE)		 4.94 13 19 24 34 40 -23
Net Nonoperating Obligations (NNO)		 -7.02 -266 -230 -279 -331 -560 -287
Total Depreciation and Amortization (D&A)		 0.21 0.28 0.90 0.67 2.37 3.05 1.51
Debt-free, Cash-free Net Working Capital to Revenue		 -25.79% 0.00% 47.52% 0.00% -5,448.34% 42.59% 3.12%
Debt-free Net Working Capital to Revenue		 44.41% 0.00% 1,192.01% 0.00% 213,854.30% 15,815.30% 120.88%
Net Working Capital to Revenue		 44.41% 0.00% 1,192.01% 0.00% 213,854.30% 15,815.30% 120.88%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.93) ($2.52) ($4.15) ($5.20) ($5.00) $2.34
Adjusted Weighted Average Basic Shares Outstanding		 0.00 23.27M 23.33M 25.24M 29.45M 37.44M 37.22M
Adjusted Diluted Earnings per Share		 $0.00 ($2.93) ($2.52) ($4.15) ($5.20) ($5.00) $2.30
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 23.27M 23.33M 25.24M 29.45M 37.44M 37.86M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.93) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 15.51M 24.00M 28.54M 35.98M 40.56M 19.72M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.39 -33 -39 -80 -119 -148 64
Normalized NOPAT Margin		 -73.94% 0.00% -196.32% 0.00% -78,780.60% -4,157.27% 26.21%
Pre Tax Income Margin		 -123.36% 0.00% -282.25% 0.00% -101,319.21% -5,269.10% 37.65%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 -7,997.83 -14,189.00 -115,403.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -5,443.32 -9,865.28 -80,353.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -8,046.83 -14,445.00 -116,644.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -5,492.32 -10,121.28 -81,594.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.50% 0.00% -0.08% -0.06% -0.09% 430.97%

Quarterly Metrics And Ratios for Keros Therapeutics

This table displays calculated financial ratios and metrics derived from Keros Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - 40,562,047.00 40,615,414.00 40,615,414.00 30,466,069.00 19,717,533.00 19,791,837.00
DEI Adjusted Shares Outstanding		 - - - - - 40,562,047.00 40,615,414.00 40,615,414.00 30,466,069.00 19,717,533.00 19,791,837.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - 3.66 -0.76 -0.18 -0.77 -1.20 -1.45
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 4,750.00% 2,027.27% 254,413.25% 49,002.70% 3,575.77% -87.34% -99.83% -100.00%
EBITDA Growth		 -36.39% -26.38% -22.07% -35.23% -21.10% 414.77% 21.83% 73.66% 44.30% -116.86% 22.87%
EBIT Growth		 -37.67% -25.73% -22.04% -35.53% -21.56% 410.10% 20.93% 73.38% 44.50% -117.17% 22.58%
NOPAT Growth		 -45.35% -24.73% -22.02% -35.53% -14.64% 519.61% 21.06% 73.77% 45.04% -112.72% 22.30%
Net Income Growth		 -35.42% -20.42% -20.67% -34.27% -14.37% 444.32% 32.17% 86.25% 49.03% -115.97% 6.47%
EPS Growth		 -22.94% 3.97% 1.57% -6.02% 15.67% 399.17% 39.20% 87.23% 66.37% -133.43% -90.79%
Operating Cash Flow Growth		 -18.73% -30.16% -29.09% 10.25% -80.71% 461.69% 25.57% 110.65% 40.68% -102.19% 31.06%
Free Cash Flow Firm Growth		 -362.37% -36.16% -18.55% 7.80% -35.85% 447.55% 36.40% 46.90% 48.61% -109.56% 66.42%
Invested Capital Growth		 165.60% 223.60% 255.53% -72.94% 990.24% -27.59% 9.74% 369.92% 35.23% -50.38% -71.46%
Revenue Q/Q Growth		 1,687.50% -41.96% -55.42% 948.65% 684.02% 6,844.31% -91.40% -21.50% -97.30% -4.68% -100.00%
EBITDA Q/Q Growth		 -1.45% -2.07% -3.48% -15.78% 9.15% 396.15% -125.60% 60.99% -87.62% 10.34% -19.33%
EBIT Q/Q Growth		 -1.50% -2.12% -3.51% -16.02% 8.96% 390.37% -126.39% 60.94% -85.44% 10.19% -19.02%
NOPAT Q/Q Growth		 -7.34% -4.37% -4.03% -16.29% 9.21% 482.01% -119.57% 61.36% -90.26% 11.59% -19.55%
Net Income Q/Q Growth		 -2.04% -7.13% -4.97% -17.01% 13.09% 422.54% -120.68% 76.28% -222.27% -1.05% -21.10%
EPS Q/Q Growth		 -0.75% 9.70% -3.31% -12.80% 19.86% 420.35% -120.99% 76.32% -111.11% -218.42% -19.83%
Operating Cash Flow Q/Q Growth		 25.08% -75.03% 10.68% 23.37% -50.85% 450.31% -118.38% 110.97% -940.01% 87.07% -478.66%
Free Cash Flow Firm Q/Q Growth		 7.94% -18.97% -10.12% 23.55% -35.65% 404.35% -120.15% 36.17% -31.28% 43.39% 29.22%
Invested Capital Q/Q Growth		 -86.59% 979.17% 30.85% -85.71% 440.31% -28.33% 98.31% -38.81% 55.49% -73.70% 14.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 -30,361.54% -58,197.59% -135,089.19% -14,915.46% -1,728.44% 71.98% -215.06% -106.87% -7,427.79% -6,986.38% 0.00%
Operating Margin		 -32,486.01% -58,413.25% -136,321.62% -15,117.78% -1,750.62% 71.97% -219.16% -107.87% -7,602.60% -7,050.95% 0.00%
EBIT Margin		 -30,768.53% -58,939.76% -136,851.35% -15,141.49% -1,758.15% 71.81% -220.38% -109.64% -7,531.69% -7,096.19% 0.00%
Profit (Net Income) Margin		 -28,141.96% -51,944.58% -122,316.22% -13,648.45% -1,513.02% 70.27% -168.96% -51.04% -6,093.77% -6,459.95% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.66% 93.66% 93.25% 83.64% 93.94% 100.00% 100.00%
Interest Burden Percent		 91.46% 88.13% 89.38% 90.14% 85.50% 104.48% 82.22% 55.66% 86.13% 91.03% 92.62%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 6.34% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -1,270.75% -2,681.62% -1,364.19% -685.73% 1,459.55% -2,262.83% -3,039.22% -95,017.98% -26,281.85% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -1,268.44% -2,678.89% -1,361.29% -683.77% 1,458.51% -2,262.32% -3,039.79% -95,017.28% -26,280.73% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 1,244.82% 2,609.74% 1,344.69% 674.17% -1,434.05% 2,198.98% 3,009.65% 92,047.43% 25,957.87% 0.00%
Return on Equity (ROE)		 -50.19% -25.92% -71.88% -19.50% -11.56% 25.50% -63.86% -29.57% -2,970.54% -323.97% 0.00%
Cash Return on Invested Capital (CROIC)		 -11,411.79% -1,774.85% -1,481.61% -2,713.38% -2,492.73% 1.92% -7.91% 514.32% 438.08% -1,172.22% -557.84%
Operating Return on Assets (OROA)		 -13.73% -31.70% -91.42% -21.77% -12.66% 24.27% -84.66% -40.92% -3,854.03% -429.35% 0.00%
Return on Assets (ROA)		 -12.56% -27.93% -81.71% -19.62% -10.90% 23.75% -64.91% -19.05% -3,118.23% -390.85% 0.00%
Return on Common Equity (ROCE)		 -50.19% -25.92% -71.88% -19.50% -11.56% 25.50% -63.86% -29.57% -2,970.54% -323.97% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -35.31% -39.93% -34.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -33 -34 -35 -41 -37 142 -28 -11 -20 -18 -22
NOPAT Margin		 -22,740.21% -40,889.28% -95,425.14% -10,582.45% -1,225.44% 67.41% -153.41% -75.51% -5,321.82% -4,935.67% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.53% -2.31% -2.73% -2.91% -1.96% 1.04% -0.52% 0.57% -0.70% -1.12% -1.49%
Return On Investment Capital (ROIC_SIMPLE)		 -9.79% - - - -6.52% 19.54% -3.94% -1.53% -6.76% -6.34% -8.26%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 6,367.13% 12,419.28% 26,921.62% 2,530.93% 350.59% 4.97% 79.71% 71.01% 3,050.13% 2,764.85% 0.00%
R&D to Revenue		 26,218.88% 46,093.98% 109,500.00% 12,686.86% 1,500.03% 23.06% 239.45% 136.86% 4,652.47% 4,386.10% 0.00%
Operating Expenses to Revenue		 32,586.01% 58,513.25% 136,421.62% 15,217.78% 1,850.62% 28.03% 319.16% 207.87% 7,702.60% 7,150.95% 0.00%
Earnings before Interest and Taxes (EBIT)		 -44 -49 -51 -59 -53 152 -40 -16 -29 -26 -31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -43 -48 -50 -58 -53 152 -39 -15 -29 -26 -31
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.59 5.25 3.92 4.09 1.12 0.57 0.77 0.91 2.05 0.76 0.81
Price to Tangible Book Value (P/TBV)		 3.59 5.25 3.92 4.09 1.12 0.57 0.77 0.91 2.05 0.76 0.81
Price to Revenue (P/Rev)		 7,888.64 10,179.70 6,084.99 3,347.02 180.63 1.93 2.33 2.60 2.54 6.56 14.11
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 98.13 28.88 9.97 7.13 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 1.02% 3.46% 10.03% 14.03% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 806.79 168.60 82.59 766.26 7.00 0.00 0.00 0.00 21.18 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 5,695.62 8,288.92 4,587.35 2,531.83 22.90 0.00 0.00 0.00 1.36 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.86 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.97 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.20 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.10 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.56 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -0.98 -0.97 -0.99 -0.99 -0.98 -0.97 -0.99 -0.97 -0.99 -0.98
Leverage Ratio		 1.11 1.08 1.09 1.09 1.09 1.07 1.08 1.07 1.09 1.08 1.08
Compound Leverage Factor		 1.02 0.95 0.97 0.99 0.93 1.12 0.88 0.60 0.94 0.98 1.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 18.11 44.39 28.28 27.64 8.20 5.72 6.86 10.36 10.16 3.53 3.19
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 14.25 24.74 20.37 19.03 21.45 19.29 21.11 29.86 15.45 22.62 21.96
Quick Ratio		 13.59 23.65 19.10 18.31 20.50 18.74 20.34 28.93 14.25 21.93 21.20
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -35 -42 -46 -35 -48 146 -29 -19 -25 -14 -9.85
Operating Cash Flow to CapEx		 -4,705.92% -4,710.36% -12,839.03% -7,901.55% -15,919.72% 28,525.84% -4,114.31% 2,371.53% -20,367.16% -4,834.25% -13,174.84%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.01 0.34 0.38 0.37 0.51 0.06 0.03
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 2.46 24.51 29.44 127.17 77.37 3.75 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.05 0.06 0.07 0.17 0.85 48.21 51.02 55.26 57.20 7.87 3.51
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 148.31 14.89 12.40 2.87 4.72 97.30 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 148.31 14.89 12.40 2.87 4.72 97.30 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1.07 12 15 2.15 12 8.33 17 10 16 4.13 4.71
Invested Capital Turnover		 -0.54 0.03 0.03 0.13 0.56 21.65 14.75 40.25 17.85 5.32 1.41
Increase / (Decrease) in Invested Capital		 2.69 7.95 11 -5.80 11 -3.17 1.47 7.96 4.10 -4.20 -12
Enterprise Value (EV)		 860 1,940 1,243 1,648 81 -307 -148 -51 333 -64 -46
Market Capitalization		 1,191 2,382 1,649 2,179 641 413 542 643 620 218 212
Book Value per Share		 $11.09 $12.62 $11.66 $14.20 $14.11 $17.97 $17.40 $17.32 $9.95 $14.49 $13.25
Tangible Book Value per Share		 $11.09 $12.62 $11.66 $14.20 $14.11 $17.97 $17.40 $17.32 $9.95 $14.49 $13.25
Total Capital		 332 454 421 533 572 729 707 704 303 286 262
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -331 -442 -406 -531 -560 -721 -690 -693 -287 -281 -258
Capital Expenditures (CapEx)		 0.54 0.95 0.31 0.39 0.29 0.57 0.72 0.14 0.13 0.07 0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.23 1.97 5.61 -7.65 1.51 -0.41 7.89 1.74 7.61 -3.67 -2.88
Debt-free Net Working Capital (DFNWC)		 323 444 411 523 561 720 698 695 295 278 255
Net Working Capital (NWC)		 323 444 411 523 561 720 698 695 295 278 255
Net Nonoperating Expense (NNE)		 7.72 9.18 9.95 12 8.75 -6.05 2.82 -3.49 2.97 5.59 7.05
Net Nonoperating Obligations (NNO)		 -331 -442 -406 -531 -560 -721 -690 -693 -287 -281 -258
Total Depreciation and Amortization (D&A)		 0.58 0.62 0.65 0.88 0.90 0.34 0.97 0.40 0.40 0.40 0.40
Debt-free, Cash-free Net Working Capital to Revenue		 -5,448.34% 839.74% 2,068.63% -1,174.35% 42.59% -0.19% 3.39% 0.71% 3.12% -11.07% -19.16%
Debt-free Net Working Capital to Revenue		 213,854.30% 189,917.95% 151,833.58% 80,343.93% 15,815.30% 335.39% 299.81% 281.79% 120.88% 837.27% 1,696.62%
Net Working Capital to Revenue		 213,854.30% 189,917.95% 151,833.58% 80,343.93% 15,815.30% 335.39% 299.81% 281.79% 120.88% 837.27% 1,696.62%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.34) ($1.21) ($1.25) ($1.41) ($1.13) $3.66 ($0.76) ($0.18) ($0.38) ($1.21) ($1.45)
Adjusted Weighted Average Basic Shares Outstanding		 29.45M 35.69M 36.10M 37.59M 37.44M 40.56M 40.61M 40.62M 37.22M 19.63M 19.80M
Adjusted Diluted Earnings per Share		 ($1.34) ($1.21) ($1.25) ($1.41) ($1.13) $3.62 ($0.76) ($0.18) ($0.38) ($1.21) ($1.45)
Adjusted Weighted Average Diluted Shares Outstanding		 29.45M 35.69M 36.10M 37.59M 37.44M 41.02M 40.61M 40.62M 37.86M 19.63M 19.80M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 35.98M 36.08M 37.52M 40.51M 40.56M 40.62M 40.62M 30.47M 19.72M 19.79M 19.83M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -34 -35 -41 -37 142 -28 -11 -20 -18 -22
Normalized NOPAT Margin		 -22,740.21% -40,889.28% -95,425.14% -10,582.45% -1,225.44% 67.41% -153.41% -75.51% -5,321.82% -4,935.67% 0.00%
Pre Tax Income Margin		 -28,141.96% -51,944.58% -122,316.22% -13,648.45% -1,503.16% 75.03% -181.19% -61.03% -6,487.01% -6,459.95% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.06% 0.00% 0.00% 0.00% -0.09% 0.00% 0.69% 0.00% 430.97% -443.15% -457.75%

Financials Breakdown Chart

Key Financial Trends

Keros Therapeutics’ financial profile remains that of a development-stage biotechnology company: revenue is inconsistent, operating losses persist, and cash reserves continue to fund research and development. The company’s balance sheet remains relatively strong, but its liquidity cushion has narrowed substantially following large share repurchases and ongoing cash burn.

Revenue fell from $211.2 million in Q1 2025, which appears to have included a significant one-time or milestone-related amount, to $18.2 million in Q2 2025, $385,000 in Q4 2025, $367,000 in Q1 2026 and zero in Q2 2026. This volatility makes revenue a poor indicator of recurring operating performance and highlights Keros’ dependence on partnership, licensing or milestone income rather than product sales.

Operating expenses have generally remained high. Research and development costs were $22.3 million in Q2 2026, while selling, general and administrative costs were $8.6 million. Total operating expenses increased to $30.9 million from $26.2 million in Q1 2026, producing a $30.9 million operating loss. The company reported a $28.7 million net loss, or $1.45 per diluted share, in the latest quarter.

Cash and equivalents declined to $257.6 million as of June 30, 2026, down from $281.5 million at the end of Q1 2026 and $720.5 million at the end of Q1 2025. Although the company has no reported debt in the provided data and liabilities totaled only $25.3 million, the decline in cash demonstrates the effect of continued losses and capital-allocation decisions.

  • Strong near-term liquidity: Keros had $257.6 million in cash and equivalents versus $12.2 million of current liabilities at June 30, 2026, implying substantial short-term balance-sheet flexibility.
  • Limited leverage: Total liabilities were just $25.3 million compared with $262.3 million of equity. The absence of meaningful reported debt reduces interest-rate and refinancing risk.
  • Research spending remains material: The company continues to invest heavily in research and development, with $22.3 million spent in Q2 2026. Sustained investment could support future clinical or licensing milestones if its pipeline advances successfully.
  • Interest income provides some support: Keros generated $2.3 million of interest and investment income in Q2 2026, partially offsetting its operating loss and reflecting the benefit of its cash reserves.
  • Cash runway is difficult to estimate precisely: Q2 operating cash outflow was $20.4 million, but cash use has varied widely because of working-capital changes, share repurchases and other nonrecurring items. At the latest quarterly operating burn rate, the cash balance appears meaningful, but future clinical spending could change the runway materially.
  • Working-capital movements have been volatile: Changes in operating assets and liabilities provided $1.9 million of cash in Q2 2026, compared with $12.9 million in Q1. This volatility can make reported cash flow differ substantially from the underlying net loss.
  • Recurring revenue remains minimal: Revenue was zero in Q2 2026 after only $367,000 in Q1, indicating that Keros currently lacks a dependable commercial revenue base.
  • Losses continue to consume capital: Keros has reported net losses in each of the recent quarters provided, including losses of $23.5 million in Q4 2025, $23.7 million in Q1 2026 and $28.7 million in Q2 2026.
  • Operating cash burn worsened sequentially: Cash used in operating activities increased from $3.5 million in Q1 2026 to $20.4 million in Q2. Continued negative operating cash flow will reduce liquidity unless revenue, partnering proceeds or financing improve.
  • Large share repurchases reduced liquidity: Keros repurchased approximately $375.0 million of common equity in Q4 2025 and another $5.7 million during the first half of 2026. While buybacks can benefit remaining shareholders if shares are undervalued, they materially contributed to the decline in cash available to fund clinical development.

Bottom line: Keros Therapeutics has a low-debt balance sheet and enough cash to provide near-term financial flexibility, but the trend is unfavorable. Revenue has effectively disappeared, operating losses are persistent, and quarterly cash burn increased in Q2 2026. Investors should focus on clinical progress, potential partnership or milestone revenue, R&D spending and the pace of cash depletion rather than on the company’s current earnings, which remain negative and highly dependent on nonrecurring revenue.

10/10/26 04:51 PM ETAI Generated. May Contain Errors.

Keros Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Keros Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Keros Therapeutics' net income appears to be on a downward trend, with a most recent value of $87.01 million in 2025, compared with -$12.34 million in 2019. The previous period was -$187.35 million in 2024. Check out Keros Therapeutics' forecast to explore projected trends and price targets.

Keros Therapeutics' total operating income in 2025 was $67.57 million, based on the following breakdown:
  • Total Gross Profit: $244.06 million
  • Total Operating Expenses: $176.49 million

Over the last 6 years, Keros Therapeutics' total revenue changed from $10 million in 2019 to $244.06 million in 2025, a change of 2,340.6%.

In the past 13 quarters, Keros Therapeutics' cash and equivalents has ranged from $257.61 million in Q2 2026 to $720.54 million in Q1 2025, and is currently $257.61 million as of their latest financial filing in Q2 2026.

Keros Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2019.

Over the last 6 years, Keros Therapeutics' book value per share changed from -8.36 in 2019 to 9.95 in 2025.


Related Companies

Financial statements for NASDAQ:KROS last updated on 8/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A simple options setup that cuts through the noise
Ian Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...
TradeWins | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel